Nitric oxide-releasing prodrug for the treatment of complex infections.

Non-tuberculosis mycobacteria (NTM) can cause severe respiratory infection in patients with underlying pulmonary conditions, and these infections are extremely difficult to treat. In this report, we evaluate a nitric oxide (NO)-releasing prodrug [methyl tris diazeniumdiolate (MD3)] against a panel of NTM clinical isolates and as a treatment for acute and chronic NTM infections . Its efficacy in inhibiting growth or killing mycobacteria was explored alongside evaluation of the impact to primary human airway epithelial tissue.